Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.25.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2024
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41463    
Entity Registrant Name bioAffinity Technologies, Inc.    
Entity Central Index Key 0001712762    
Entity Tax Identification Number 46-5211056    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 3300 Nacogdoches Road    
Entity Address, Address Line Two Suite 216    
Entity Address, City or Town San Antonio    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 78217    
City Area Code (210)    
Local Phone Number 698-5334    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 22.6
Entity Common Stock, Shares Outstanding   18,255,824  
Documents Incorporated By Reference Portions of the registrant’s definitive proxy statement relating to the 2025 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2024 (the “2025 Proxy Statement”).    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.007    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of bioAffinity Technologies, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with principles generally accepted in the United States of America.    
Auditor Name WithumSmith+Brown, PC    
Auditor Location New York, New York    
Auditor Firm ID 100    
Common Stock Par Value 0.007 Per Share [Member]      
Title of 12(b) Security Common stock, par value $0.007 per share    
Trading Symbol BIAF    
Security Exchange Name NASDAQ    
Tradeable Warrants To Purchase Common Stock [Member]      
Title of 12(b) Security Tradeable Warrants to purchase Common Stock    
Trading Symbol BIAFW    
Security Exchange Name NASDAQ